利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

112 条记录 (耗时 0.039 秒)

    Piperazine-piperidines with CXCR3 antagonist activity
    1.
    发明申请
    Piperazine-piperidines with CXCR3 antagonist activity 有权
    哌嗪 - 哌啶与CXCR3拮抗剂活性

    公开(公告)号：US20060276457A1

    公开(公告)日：2006-12-07

    申请号：US11353806

    申请日：2006-02-14

    申请人： Wensheng Yu ,  Seong Kim ,  Gopinadhan Anilkumar ,  Stuart Rosenblum ,  Bandarpalle Shankar ,  Brian McGuinness ,  Douglas Hobbs ,  Yuefei Shao

    发明人： Wensheng Yu ,  Seong Kim ,  Gopinadhan Anilkumar ,  Stuart Rosenblum ,  Bandarpalle Shankar ,  Brian McGuinness ,  Douglas Hobbs ,  Yuefei Shao

    IPC分类号： A61K31/551 ,  A61K31/498 ,  A61K31/496 ,  A61K31/525 ,  C07D487/02 ,  C07D475/02

    CPC分类号： C07D487/04 ,  C07D401/12

    摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

    摘要翻译： 本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐，溶剂合物或酯的化合物或对映异构体，立体异构体，旋转异构体，互变异构体或前药，所述化合物具有式1所示的一般结构 ：或其药学上可接受的盐，溶剂合物或酯，其中各种部分在本文中定义。 还公开了治疗趋化因子介导的疾病的方法，例如姑息治疗，疗效治疗，某些疾病和疾病如炎性疾病的预防性治疗（非限制性实例，牛皮癣），自身免疫性疾病（非限制性的 例如，类风湿性关节炎，多发性硬化症），移植排斥反应（非限制性实例包括，同种异体移植排斥反应，异种移植物排斥），感染性疾病（例如结核性麻风病），固定药物爆发，皮肤迟发型超敏反应 应答，眼部炎症，I型糖尿病，病毒性脑膜炎和使用式1的化合物的肿瘤。

    Heterocyclic substituted piperazines with CXCR3 antagonist activity
    4.
    发明申请
    Heterocyclic substituted piperazines with CXCR3 antagonist activity 有权
    具有CXCR3拮抗剂活性的杂环取代哌嗪

    公开(公告)号：US20060276479A1

    公开(公告)日：2006-12-07

    申请号：US11353641

    申请日：2006-02-14

    申请人： Seong Kim ,  Gopinadhan Anilkumar ,  Michael Wong ,  Qingbei Zeng ,  Stuart Rosenblum ,  Joseph Kozlowski ,  Yuefei Shao ,  Brian McGuinness ,  Douglas Hobbs

    发明人： Seong Kim ,  Gopinadhan Anilkumar ,  Michael Wong ,  Qingbei Zeng ,  Stuart Rosenblum ,  Joseph Kozlowski ,  Yuefei Shao ,  Brian McGuinness ,  Douglas Hobbs

    IPC分类号： A61K31/497 ,  C07D413/14 ,  C07D403/14

    CPC分类号： C07D401/12 ,  C07D401/14 ,  C07D413/14 ,  C07D417/14

    摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, ophthalmic inflammation, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

    摘要翻译： 本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐，溶剂合物或酯的化合物或对映异构体，立体异构体，旋转异构体，互变异构体或前药，所述化合物具有式1所示的一般结构 ：或其药学上可接受的盐，溶剂合物或酯，其中各种部分在本文中定义。 还公开了治疗趋化因子介导的疾病的方法，例如姑息治疗，疗效治疗，某些疾病和疾病如炎性疾病的预防性治疗（非限制性实例，牛皮癣），自身免疫性疾病（非限制性的 例如，类风湿性关节炎，多发性硬化症），移植排斥反应（非限制性实例包括，同种异体移植排斥反应，异种移植物排斥），感染性疾病（例如结核性麻风病），固定药物爆发，皮肤迟发型超敏反应 应答，眼部炎症，I型糖尿病，病毒性脑膜炎和使用式1的化合物的肿瘤。

    Substituted heterocyclic compounds with CXCR3 antagonist activity
    6.
    发明申请
    Substituted heterocyclic compounds with CXCR3 antagonist activity 有权
    取代的具有CXCR3拮抗剂活性的杂环化合物

    公开(公告)号：US20070082913A1

    公开(公告)日：2007-04-12

    申请号：US11545201

    申请日：2006-10-10

    申请人： Seong Kim ,  Bandarpalle Shankar ,  Joseph Kozlowski ,  Stuart Rosenblum ,  Neng-Yang Shih

    发明人： Seong Kim ,  Bandarpalle Shankar ,  Joseph Kozlowski ,  Stuart Rosenblum ,  Neng-Yang Shih

    IPC分类号： A61K31/497 ,  A61K31/496 ,  C07D403/14

    CPC分类号： C07D401/14 ,  C07D401/08 ,  C07D413/14

    摘要： The present application discloses a compound, or enantiomers, stereoisomers, rotamers, tautomers, racemates or prodrug of said compound, or pharmaceutically acceptable salts, solvates or esters of said compound, or of said prodrug, said compound having the general structure shown in Formula 1: or a pharmaceutically acceptable salt, solvate or ester thereof, wherein the various moieties are defined herein. Also disclosed is a method of treating chemokine mediated diseases, such as, palliative therapy, curative therapy, prophylactic therapy of certain diseases and conditions such as inflammatory diseases (non-limiting example(s) include, psoriasis), autoimmune diseases (non-limiting example(s) include, rheumatoid arthritis, multiple sclerosis), graft rejection (non-limiting example(s) include, allograft rejection, xenograft rejection), infectious diseases (e.g, tuberculoid leprosy), fixed drug eruptions, cutaneous delayed-type hypersensitivity responses, type I diabetes, viral meningitis and tumors using a compound of Formula 1.

    摘要翻译： 本申请公开了所述化合物或所述前体药物的所述化合物或其药学上可接受的盐，溶剂合物或酯的化合物或对映异构体，立体异构体，旋转异构体，互变异构体或前药，所述化合物具有式1所示的一般结构 ：或其药学上可接受的盐，溶剂合物或酯，其中各种部分在本文中定义。 还公开了治疗趋化因子介导的疾病的方法，例如姑息治疗，疗效治疗，某些疾病和疾病如炎性疾病的预防性治疗（非限制性实例，牛皮癣），自身免疫性疾病（非限制性的 例如，类风湿性关节炎，多发性硬化症），移植排斥反应（非限制性实例包括，同种异体移植排斥反应，异种移植物排斥），感染性疾病（例如结核性麻风病），固定药物爆发，皮肤迟发型超敏反应 应答，I型糖尿病，病毒性脑膜炎和使用式1的化合物的肿瘤。

    Approach for printing policy-enabled electronic documents using locked printing and a shared memory data structure
    10.
    发明授权
    Approach for printing policy-enabled electronic documents using locked printing and a shared memory data structure 有权
    使用锁定打印和共享内存数据结构打印启用政策的电子文档的方法

    公开(公告)号：US09311031B2

    公开(公告)日：2016-04-12

    申请号：US12059986

    申请日：2008-03-31

    申请人： Seiichi Katano ,  Jayasimha Nuggehalli ,  Seong Kim

    发明人： Seiichi Katano ,  Jayasimha Nuggehalli ,  Seong Kim

    IPC分类号： G06F15/00 ,  G06F3/12 ,  G06F21/60

    CPC分类号： G06F3/1238 ,  G06F3/1222 ,  G06F3/1288 ,  G06F21/608

    摘要： According to approach for printing policy-enabled electronic documents, when a locked print module determines that an electronic document contained in the PDF print data is a policy-enabled electronic document, the locked print module causes the PDF print data to be stored on the printing device and not immediately processed for printing. A PDF-to-postscript conversion module generates and stores in a common data structure in the shared memory a request for security data for the PDF print data. A policy client module retrieves the request from the common data structure in the shared memory, obtains security data for the PDF print data from a policy server, and stores the security data in the common data structure in the shared memory. The PDF-to-postscript conversion module uses the security data to decrypt the PDF print data and then converts the decrypted PDF print data into postscript data for printing by the printing device.

    摘要翻译： 根据用于打印启用政策的电子文档的方法，当锁定的打印模块确定PDF打印数据中包含的电子文档是启用政策的电子文档时，锁定的打印模块使PDF打印数据存储在打印 设备，而不是立即处理打印。 PDF到后记转换模块在共享存储器中的通用数据结构中生成并存储对PDF打印数据的安全数据的请求。 策略客户端模块从共享存储器中的公共数据结构检索请求，从策略服务器获取PDF打印数据的安全数据，并将公共数据结构中的安全数据存储在共享存储器中。 PDF到后记转换模块使用安全数据来解密PDF打印数据，然后将解密的PDF打印数据转换成postscript数据以供打印设备打印。